Lincoln Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Lincoln Pharmaceuticals CEO'su Mahendrabhai Patel, Jun2018 tarihinde atandı, in görev süresi 6.42 yıldır. in toplam yıllık tazminatı ₹ 4.93M olup, şirket hissesi ve opsiyonları dahil olmak üzere 99.4% maaş ve 0.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 6.52% ine doğrudan sahiptir ve bu hisseler ₹ 804.82M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6 yıl ve 10 yıldır.

Anahtar bilgiler

Mahendrabhai Patel

İcra Kurulu Başkanı

₹4.9m

Toplam tazminat

CEO maaş yüzdesi	99.4%
CEO görev süresi	6.4yrs
CEO sahipliği	6.5%
Yönetim ortalama görev süresi	6yrs
Yönetim Kurulu ortalama görev süresi	10yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Mahendrabhai Patel'un ücretlendirmesi Lincoln Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	₹966m
Jun 30 2024	n/a	n/a	₹980m
Mar 31 2024	₹5m	₹5m	₹933m
Dec 31 2023	n/a	n/a	₹873m
Sep 30 2023	n/a	n/a	₹808m
Jun 30 2023	n/a	n/a	₹769m
Mar 31 2023	₹3m	₹3m	₹729m
Dec 31 2022	n/a	n/a	₹714m
Sep 30 2022	n/a	n/a	₹674m
Jun 30 2022	n/a	n/a	₹667m
Mar 31 2022	₹3m	₹3m	₹694m
Dec 31 2021	n/a	n/a	₹709m
Sep 30 2021	n/a	n/a	₹668m
Jun 30 2021	n/a	n/a	₹647m
Mar 31 2021	₹3m	₹3m	₹623m
Dec 31 2020	n/a	n/a	₹586m
Sep 30 2020	n/a	n/a	₹560m
Jun 30 2020	n/a	n/a	₹540m
Mar 31 2020	₹2m	₹2m	₹514m
Dec 31 2019	n/a	n/a	₹510m
Sep 30 2019	n/a	n/a	₹492m
Jun 30 2019	n/a	n/a	₹453m
Mar 31 2019	₹2m	₹2m	₹487m
Dec 31 2018	n/a	n/a	₹470m
Sep 30 2018	n/a	n/a	₹495m
Jun 30 2018	n/a	n/a	₹458m
Mar 31 2018	₹2m	₹2m	₹346m

Tazminat ve Piyasa: Mahendrabhai 'nin toplam tazminatı ($USD 58.43K ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 42.72K ).

Tazminat ve Kazançlar: Mahendrabhai 'in maaşı son bir yılda %20'den fazla arttı.

CEO

Mahendrabhai Patel (70 yo)

6.4yrs

Görev süresi

₹4,925,000

Tazminat

Mr. Mahendrabhai Gulabdas Patel, B.A, LLB serves as Managing Director of Lincoln Pharmaceuticals Ltd since June 08, 2018. Mr. Patel has varied experience of chemicals, steel, finance etc. Mr. Patel handles...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mahendrabhai Patel	MD & Whole Time Director	6.4yrs	₹4.93m	6.52% ₹ 804.8m
Darshit Shah	Chief Financial Officer	5.7yrs	₹1.32m	Veri yok
Trusha Shah	Company Secretary & Compliance Officer	2yrs	₹589.00k	Veri yok
Ashish Patel	Whole Time Director	no data	₹6.64m	10.6% ₹ 1.3b
Hashmukhbhai Patel	Whole Time Director	29.8yrs	₹3.81m	1.87% ₹ 230.2m
Munjal Patel	Whole Time Director	no data	₹6.65m	13.37% ₹ 1.7b
Sanjay Bhatt	Senior Manager of Operation	no data	Veri yok	Veri yok
Laxmikant Harsola	Vice President of Technical	no data	Veri yok	Veri yok
Sanjiv Patel	Senior Manager of Planning & Administration	no data	Veri yok	Veri yok
Amit Dwivedi	Group Marketing Manager	no data	Veri yok	Veri yok
Anil Verma	Sales and Distributor Head	no data	Veri yok	Veri yok
Sachin Kapoor	Head of H R D	no data	Veri yok	Veri yok

6.0yrs

Ortalama Görev Süresi

45.5yo

Ortalama Yaş

Deneyimli Yönetim: 531633 'un yönetim ekibi deneyimli ve deneyimlidir ( 6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mahendrabhai Patel	MD & Whole Time Director	29.8yrs	₹4.93m	6.52% ₹ 804.8m
Ashish Patel	Whole Time Director	10yrs	₹6.64m	10.6% ₹ 1.3b
Hashmukhbhai Patel	Whole Time Director	29.8yrs	₹3.81m	1.87% ₹ 230.2m
Munjal Patel	Whole Time Director	10yrs	₹6.65m	13.37% ₹ 1.7b
Rajnikant Patel	Non-Executive Director	29.8yrs	Veri yok	3.78% ₹ 466.3m
Kishorbhai Shah	Non-Executive Chairman	29.3yrs	Veri yok	2.39% ₹ 294.8m
Saurin Jagdish Parikh	Independent Non-Executive Director	6.7yrs	Veri yok	Veri yok
Nareshkumar Suthar	Independent Director	less than a year	Veri yok	Veri yok
Seema Mehta	Woman Independent Director	less than a year	Veri yok	Veri yok

10.0yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 531633 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10 yıldır).

Lincoln Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Lincoln Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024

Lincoln Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024

Whole Time Director recently bought ₹20m worth of stock

Lincoln Pharmaceuticals Limited Announces Resignation of Meha Patel as Non-Executive Independent women Director

Insider recently bought ₹13m worth of stock

Whole Time Director recently bought ₹15m worth of stock

Recent updates

Second quarter 2025 earnings released: EPS: ₹13.15 (vs ₹13.81 in 2Q 2024)

Lincoln Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 14, 2024

Lincoln Pharmaceuticals Limited Declarers Dividend for the Financial Year 2023-2024

Dividend increased to ₹1.80

Lincoln Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024

Lincoln Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024

First quarter 2025 earnings released: EPS: ₹11.82 (vs ₹9.49 in 1Q 2024)

Lincoln Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 08, 2024

Lincoln Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 08, 2024

Whole Time Director recently bought ₹20m worth of stock

Full year 2024 earnings released: EPS: ₹46.58 (vs ₹36.40 in FY 2023)

Lincoln Pharmaceuticals Limited Recommends Dividend for the Year Ended March 31, 2024

Now 20% overvalued

Now 22% overvalued

Now 24% overvalued

Lincoln Pharmaceuticals Limited Announces Resignation of Meha Patel as Non-Executive Independent women Director

Insider recently bought ₹13m worth of stock

Third quarter 2024 earnings released: EPS: ₹14.00 (vs ₹10.79 in 3Q 2023)

Lincoln Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 08, 2024

Second quarter 2024 earnings released: EPS: ₹13.81 (vs ₹11.84 in 2Q 2023)

Lincoln Pharmaceuticals Limited Declares Dividend for the Financial Year 2022-23

Upcoming dividend of ₹1.50 per share at 0.3% yield

Lincoln Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 14, 2024

Whole Time Director recently bought ₹15m worth of stock

First quarter 2024 earnings released: EPS: ₹9.49 (vs ₹7.49 in 1Q 2023)

First quarter 2024 earnings released: EPS: ₹9.49 (vs ₹7.49 in 1Q 2023)

Whole Time Director recently bought ₹15m worth of stock

Full year 2023 earnings released: EPS: ₹36.40 (vs ₹34.63 in FY 2022)

Lincoln Pharmaceuticals Limited Approves the Resignation of Anand A. Patel from the Position of Whole Time Director as Well as Director of the Company

Lincoln Pharmaceuticals Limited to Report Q4, 2023 Results on May 25, 2023

Whole Time Director recently bought ₹5.0m worth of stock

Third quarter 2023 earnings released: EPS: ₹10.79 (vs ₹8.79 in 3Q 2022)

Lincoln Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 09, 2023

Lincoln Pharmaceuticals Limited Informs About Demise of Shri Ishwarlal Ambalal Patel Independent Director

MD & Whole Time Director recently bought ₹20m worth of stock

MD & Whole Time Director recently bought ₹9.9m worth of stock

Less than half of directors are independent

Lincoln Pharmaceuticals Limited Appoints Trusha Shah as Company Secretary and Compliance Officer

Lincoln Pharmaceuticals Limited Approves to Declare Dividend for the Financial Year 2021-22

Upcoming dividend of ₹1.50 per share

Lincoln Pharmaceuticals Limited Proposes to Declare Dividend for the Financial Year 2021-2022

Lincoln Pharmaceuticals Limited Proposes to Declare Dividend for the Financial Year 2021-2022

Lincoln Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2022

Lincoln Pharmaceuticals Limited Approves Appointment of Anand A. Patel as an Additional and Whole Time Director

First quarter 2023 earnings released: EPS: ₹7.49 (vs ₹8.85 in 1Q 2022)

Lincoln Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 09, 2022

Lincoln Pharmaceuticals Limited Announces Resignation of Niren A. Desai as Company Secretary / Compliance Officer, with Effect from July 19, 2022

Board Member recently bought ₹20m worth of stock

Whole Time Director recently bought ₹20m worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Lincoln Pharmaceuticals Limited Recommends Dividend for the Year Ended March 31, 2022

Less than half of directors are independent

Whole Time Director recently bought ₹6.0m worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Lincoln Pharmaceuticals Limited to Report Q3, 2022 Results on Feb 10, 2022

Board Member recently bought ₹8.2m worth of stock

Lincoln Pharmaceuticals Limited (BSE:531633) acquired plant in Mehsana, Gujarat for INR 300 million.

MD & Whole Time Director recently bought ₹15m worth of stock

Investor sentiment improved over the past week

Board Member recently bought ₹11m worth of stock

Whole Time Director recently bought ₹12m worth of stock

First quarter 2022 earnings released: EPS ₹8.85 (vs ₹7.63 in 1Q 2021)

Whole Time Director recently bought ₹16m worth of stock

Full year 2021 earnings released: EPS ₹31.11 (vs ₹25.72 in FY 2020)

Lincoln Pharmaceuticals Limited Recommends Dividend for the Year Ended March 31, 2021

New 90-day high: ₹250

Whole Time Director recently bought ₹8.3m worth of stock

Whole Time Director recently bought ₹30m worth of stock

New 90-day low: ₹216